Two carboxy-terminal truncated forms of the pAPP, pAPP-751 and pAPP-770. are shown to be the predominant isoforms secreted by platelets. The release of pAPP from platelets is responsible for the higher concentration of pAPP in serum compared with plasma, and thrombin doseresponse data show that release of pAPP is most consistent with a granule localization within the platelet. Thrombin HE A-4 PROTEIN or P-amyloid protein ( P A P ) is a T 4.2-Kd polypeptide that constitutes a major proteinaceous component of the amyloid deposits that accumulate in patients with Alzheimer's disease, Down syndrome, the cerebral amyloid angiopathies, and Guamanian parkinsonism-dementia.1-6 Molecular biology techniques have determined that the PAP sequence is contained in four alternatively spliced products from a single gene on human chromosome 2L7-l* These P-amyloid precursor proteins (PAPP) seem to be the source of the PAP deposited as amyloid in the aforementioned illnesses, though the pathogenesis of these lesions has yet to be determined.
T 4.2-Kd polypeptide that constitutes a major proteinaceous component of the amyloid deposits that accumulate in patients with Alzheimer's disease, Down syndrome, the cerebral amyloid angiopathies, and Guamanian parkinsonism-dementia.1-6 Molecular biology techniques have determined that the PAP sequence is contained in four alternatively spliced products from a single gene on human chromosome 2L7-l* These P-amyloid precursor proteins (PAPP) seem to be the source of the PAP deposited as amyloid in the aforementioned illnesses, though the pathogenesis of these lesions has yet to be determined.
The forms of PAPP that have been identified consist of 695, 714, 751, and 770 amino acids (Fig l) .9J2-15 All resemble transmembrane proteins and contain a small cytosolic carboxy-terminal tail, a single transmembrane region, and a long extracellular extension. The PAP straddles the outer leaflet of the plasma membrane. PAPP-714 and PAPP-751 are identical to PAPP-695 except that they contain additional polypeptide sequences encoded by different exons inserted after exon 6.16 The PAPP-751 insert consists of 56 amino acids homologous to a Kunitz-type serine protease inhibitor domain. The insert in PAPP-714 contains 19 amino acids with sequence homology to a surface glycoprotein found on neurons, thymocytes, and endothelial cells called MRC OX-2.I5 PAPP-770 contains both these domains sequentially inserted with the MRC OX-2 sequence directly following the Kunitz domain. A putative secretory variant of the PAPP has also been described whose initial 543 amino-terminal amino acids (13 exons) are identical to those of PAPP-751, but the carboxy-
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 terminal segment containing the cytosolic tail, transmembrane region, PAP, and a portion of the extracellular domain is replaced by 20 amino acids homologous to an Alu repeat sequence.17 Because this variant is not capable of generating the P A P , it is referred to as a PAPP-related protein (PAPPr). Though synthesized as potential transmembrane proteins, PAPP can also be secreted. Secreted forms of PAPP are known to be released from cells following posttranslational proteolytic cleavage (Fig 1) . This normal processing of the PAPP results in cleavage between either Gln-15 and Lys-16 or Lys-16 and Leu-17 of the PAP,18,19 resulting in the carboxy-terminal27 amino acids of the PAP being retained with the transmembrane/cytosolic tail remnant, whereas the amino-terminal 15 amino acids of the PAP comprise the carboy-terminal end of the secreted protein product. This processing precludes the generation of the intact 42-amino acid PAP found in the disease-associated amyloid deposits.
Platelets secrete a potent factor XIa inhibitory activity when stimulated by thrombin, collagen, adenosine diphosphate (ADP), or the calcium ionophore A23187.20, 21 We have previously shown that a form of the PAPP containing the Kunitz proteinase inhibitory domain is released by activated platelets and is a potent inhibitor of factor XIa with a Ki = 450 pmol/L.22 Here we report that carboxyterminal-truncated forms of PAPP-751 and PAPP-770 account for the vast majority of PAPP secreted by platelets, and demonstrate that the characteristics of the release of PAPP from platelets is consistent with that of an c1 granule constituent, substantiating a previous report localizing platelet PAPP to (Y granules by sucrose density gradient centrifugation.*3 We also report that thrombin cleaves secreted forms of the PAPP at a site amino-terminal to the PAP. succinic acid, 1 mmol/L EDTA, 50 pg/mL polybrene, 1 mmol/L benzamidine, 0.02% NaN3, pH 8.35. The effluent containing factor XI activity, as determined by standardized clotting assay, was dialyzed into 0.05 mol/L sodium acetate, 1 mmol/L EDTA, 1 mmol/L benzamidine, pH 5.2, and loaded onto a 200-cm3 SSepharose fast-flow column at 200 cm3/h. Factor XI was eluted by forming a linear salt gradient using 1.5 L of start buffer and 1.5 L of start buffer and 0.7 mol/L NaCI. Fractions containing factor XI activity were pooled and dialyzed against Tris-saline (0.05 mol/L Tris, 0.10 mol/L NaCI, 0.02% NaN3, pH 7.5) before affinity chromatography using a murine monoclonal antibody (MoAb) directed against human factor XI. Following 2 mol/L NaSCN elution and dialysis into Tris-saline, factor XI was activated by the addition of human factor XIIa (5:1 wt/wt) (Enzyme Research Laboratories, South Bend, IN); factors XIa and XIIa were separated by repassage over the monoclonal XI column. The final product was judged to be greater than 98% factor XIa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and did not contain redldual factor XIIa activity. Radiolabeled factor XIa was prepared using lzI and Iodogen as per the manufacturer's instructions (Pierce Chemical Co, Rockford, IL).
Thrombin was prepared as describedz and was standardized against 530 NIH U/mL thrombin (Sigma) by coagulation assay.
Kunitz domain-containing forms of the PAPP were purified from Hep G2 media as previously described.22 Where indicated, partial purification of PAPP was performed using heparin agarose (Sigma) equilibrated in Tris-saline and eluted with either SDS-PAGE sample buffer containing 4% SDS or 0.5 mol/L sodium chloride. Recombinant PAPP-751 (rPAPP-751) was provided by Athena Neurosciences (San Francisco, CA).
Collection and assay ofplatelets, platelet releasate, and white blood cells (WBCs). Platelets were prepared from freshly collected human blood using differential centrifugation?6 Platelet preparations contained no detectable leukocytes or red blood cells (RBCs) as determined by Coulter countet (Coulter Electronics, Hialeah, FL) analysis and Wright's stain. Platelets at 1 X 109/mL were activated using 0.5 U/mL human thrombin or 1 The functional factor XIa inhibitory activity in platelet releasate was determined using the factor XIa chromogenic substrate S2366 (Kabi). Factor XIa at 100 ng/mL final concentration was incubated with varying volumes of platelet releasate brought to a final volume of 900 pL with TJ3SA. After 15 minutes incubation at room temperature, 100 pL of 3 mmol/L S2366 in water was added and the absorbance at 405 nm measured three times per minute for 60 to 90 minutes on a spectrometer (Response UV-VIS; Gilford Systems, Ciba Corning, Oberlin, OH). The degree of inhibition was determined by comparing the remaining steady-state factor XIa activity with that of factor XIa in the absence of releasate.
Releasate was selectively cleared of Kunitz domain-containing forms of PAPP by affinity chromatography using a MoAb directed against the PAPP Kunitz domain (see below). Releasate was loaded onto a 2 to 3 cm3 M o A b -a g e 1 10 column at a rate of 5 to 10 mL/h. The flow-through was collected in 750-pL samples and the column washed with Trig-saline before elution with 2 mol/L NaSCN. After dialyzing (2,000 molecular weight cut-of€) the eluent into Tris-saline, samples were subjected to factor XIa ligand blot and assayed for functional factor XIa activity as described. A similar experiment was performed in parallel using an unrelated MoAb-affinity column (antifactor X, see below) as a control for nonspecific binding.
Factor XIa ligand blotting was performed on samples following SDS-PAGE and subsequent transfer to nitrocellulose paper. Blots
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were blocked with 5% defatted milk and incubated overnight with IZ5I-factor Xla at room temperature. Autoradiography for 3 to I2 hours at -70°C was performed following extensive washing of the blot in 5% defatted milk. Quantitation of released factor Xla inhibitor was determined by densitometry measurement of bound 1L51-labeled factor Xla using an LKB 2222-020 Ultrascan XL laser densitometer (LKB, Brommer, Sweden).
WBCs were separated into a polymorphonuclear fraction and a mononuclear fraction consisting of monocytes and lymphocytes using Mono-Poly Resolving Medium Ficoll-Hypaque following the manufacturer's recommendations (ICN Flow, Costa Mesa, CA).
Final samples contained I0.000 to 20,000 mononuclear cellsh" (10% to 25% monocytes, 75Q to 90% lymphocytes) and 30,000 10 60.000 polymorphonuclear cells/mm3. For ligand blots, approximately 20 pL of each preparation was loaded per lane. Less than 5% cross-contamination between leukocyte fractions was observed, and fewer than 5,000 plateletsh" were present in either leukocyte fraction as determined by Coulter counter.
New Zealand white rabbits were immunized with PAPP purified from HepG2 cells?? (anti-Xlal) or peptides representing different domains of the PAPP coupled to keyhole lymphocyte hemocyanin (KLH). The peptides used were EVPTDGNAGLLAEPQIAMF of t he amino-terminus (anti-NH2); RAMISRWYFDVTEGKC of the Kunitz proteinase inhibitory domain (anti-Kunitz): MSQSLLKTTQEPLARDPVKL representing the 19 amino acid MRC OX-2 insert encoded by exon 8 (anti-MRC OX-2); DELLOKEQNYSDDVLANMIS representing the amino-terminus of the region encoded by exon 14 (anti-exon 14); DAEFRHDSGYEVHHOKLVFFAEDV of the amino terminus of the P-amyloid protein (anti-PAP1): and GYENPTYK-FFEQMQN of the cytoplasmic tailIcarboxy-terminus (anti-COOH). The peptide representing the PAP was also used to immunize rabbits without prior coupling to KLH (anti-PAP2). An MoAb against the Kunitz domain of PAPP was obtained from Athena Neurosciences (San Francisco, CA).
Samples for Western blotting were subjected to SDS-PAGE and transferred to nitrocellulose paper. Antisera were used at 1:100 dilutions in TBSA/Tween (0.15 mollL Tris, 0.10 mol/L NaCI, 0.1% TBSA, 0.05% Tween 20. pH 7.5) and allowed to incubate with the samples for 2 to 4 hours. Following extensive washing with 5% defatted milk, the blots were incubated with the secondary antibody coupled to alkaline phosphatase (Sigma) for 30 10 90 Anrihody prepamtion.
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116.5-minutes and developed per manufacturer's protocol. To confirm specificity. antisera were preincubated with appropriate peptide at concentrations of 10 to 100 GglmL for 6 to 12 hours before use. The polyclonal antibody developed against Hep G2 factor Xla inhibitor, the monoclonal preparation against the Kunitz domain, and a monoclonal developed against factor X (3618) were chromatographed over Protein A Agarose (Repligen Corp, Cambridge, MA) before linking to Affigel IO (Bio Rad, Richmond. CA) at 3 to 5 mg immunoglobinlmL Atfigel 10 per manufacturer's specifications.
Cultured human kidney 293 (ATCC CRL 1573) cells were cotransfected with vector containing the PAPP-751 sequence (pSV-751-TM from Athena Neurosciences) and a vector conferring neomycin resistance (pSV2-neo) using a calcium phosphate protocol (Stratagene, La Jolla, CA). The antibiotic G418 was used for selection, and clones were screened for production of PAPP-751 by ligand blot as described above.
The transfected 293 cells were harvested with trypsin, washed in sterile Tris-saline, and resuspended in Tris-saline containing 1 % Triton X-100. Following sonication and centrifugation the supernatant was subjected to SDS-PAGE with subsequent transfer to nitrocellulose paper and blotting with various anti-PAPP antisera.
RESULTS
Factor XIa ligand blotting of SDS-lyscd platclcts dctccts a broad band of factor XIa binding at 112 Kd (Fig 2) . Following platclct activation with 1 mmol/L calcium ionophorc A23187 or 0.5 U/mL thrombin, this factor XIa binding activity is found in thc platclct rclcasatc and is no longcr associated with thc platclct pcllct. Figurc 2 shows also that affinity chromatography using an MoAb dircctcd against thc Kunitz domain of pAPP rcmovcs all factor Xla binding dctcctablc by ligand blot from platclct rclcasatc.
Following activation of platclcts by thrombin, platelet pAPP undcrgocs additional protcolytic cleavage with a reduction in thc intensity of thc broad signal at 112 Kd and thc appcarancc of a doublct with a rclative molccular mass of 90 to 95 Kd (Figs 2, 3) . With highcr Concentrations of thrombin (Fig 3A) Proteolysis of pAPP in platelet releasate. 112-Kd signal is convcrtcd to the lower molecular weight doublet. Thcrc docs not secm to be additional sites of protcolysis and, morc spccifically, there is no indication that thc lower molecular weight member of the doublet is a proteolytic fragmcnt of the highcr molecular wcight mcmbcr of the doublct (Figs 3A, 3B) .
Thrombin sccms rcsponsiblc for this proteolysis because: (1) it is not sccn to thc same degree during the same time period when calcium ionophorc A23187 is used as the platclet agonist (Fig 2) ; (2) there is a dosc-rcsponsc rclationship bctwccn thrombin concentrations and the dcgrec of PAPP clcavagc in platelct rclcasate ( Fig 3A) ; (3) thrombin clcavcs rPAPP-751 in a purified systcm ( Fig 3C) ; and (4) hirudin, a potcnt and specific inhibitor of thrombin, blocks the proteolysis of both purificd rpAPP-751 and PAPP prcscnt in platclet rclcasatc (Fig 3C) . Furthcrmorc, thrombin's clcavagc of rPAPP-75 1 involves a similar carboxytcrminal truncation as seen in platelct rcleasatc, because thc amino-tcrminal-dircctcd antibody rccognizcs thc clcavcd moiety (Fig 3C) . This carboxy-terminal proteolysis does not significantly alter the factor XIa inhibitory propertics of PAPP (data not shown).
Western blots using polyclonal antibodies dcvelopcd against specific regions of thc PAPP indicate that carboy-tcrminal truncated forms of PAPP containing the Kunitz domain predominate in platclct rclcasatc. The factor Xla binding activity at 112 Kd comigrates with bands recognized by antibodics directcd against thc PAPP purificd from Hep G2 mcdia as well as antipcptide antibodics devclopcd against the aminoterminus, the Kunitz domain, thc MRC OX-2 insert, and thc PAP of PAPP (Fig 4A) . Antibodics dcvclopcd against the carboy-tcrminal pcptidc scqucncc do not rccognizc protcins in platelet rclcasatc (Fig 4A) but do rccognizc full-length forms of PAPP in a transfected cell lysatc ( Fig  4B) . This pattcrn is similar to that prcviously rcportcd for sccretcd forms of PAPP with thc 15 amino acid PAP rcmnant on the sccrctcd form accounting for the retained signal obscrvcd with antiscra dircctcd against thc PAP (Fig  l) .txJ9 In addition, when platclct rclcasate is sclcctivcly Types of W P P in platelet releasate. When thrombin is used to activate platelets the PAPP signal consists of a doublet at 90 to 95 Kd in addition to the band at 112 Kd (Figs 2 and 3) . Figure 4C shows a Western blot of a releasate sample from thrombin-activated platelets in which this conversion is approximately half complete. The 112-Kd parent species and both members of the 90-to 95-Kd doublet are recognized by antibodies directed against the amino-terminus, Kunitz domain, and exon 14 region of the PAPP. The antisera to the PAP region recognizes the 112-Kd band but neither member of the 90-to 95-Kd doublet suggesting proteolytic loss of this carboxy-terminal epitope in the doublet. Only the higher molecular weight moiety in the 90-to 95-Kd doublet yields a signal with antisera against the MRC OX-2. This pattern is most consistent with the 95-Kd band being a carboxy-terminaltruncated form of PAPP-770 and the 90-Kd band being a carboxy-terminal-truncated form of PAPP-75 1.
Characteristics of W P P release by platelets. Figure 5 compares the thrombin-mediated release of platelet PAPP with that of known CY granule (PF4), dense body (serotonin), and lysosomal (phex) constituents. Each of these separate platelet compartments has a different threshold for release in response to thrombin stimulation. Using four platelet preparations and thrombin concentrations run in duplicate, the thrombin concentration required for 50% maximal inducible release of PF4 was determined to be 0.045 f 0.009 U/mL, whereas the thrombin concentration for 50% release of serotonin and phex was 0.078 2 0.01 U/mL and 0.3 -t 0.03 U/mL, respectively. The concentration of thrombin required for 50% release of platelet PAPP was 0.037 ? 0.015 U/mL, nearly identical to that of PF4. Two-tailed t-test showed a significant difference in thrombin concentrations inducing 50% release of Phex and serotonin (P < .OOl), PF4 and serotonin (P < .Ol), and release of PAPP compared with phex and serotonin (P < .001 andP < .01, respectively). The thrombin concentrations required for 50% release of PF4 and PAPP were not statistically different.
Contribution of W P P to XIa inhibitory activity in platelet releasate. To determine the contribution of platelet- releasable PAPP to the overall factor XIa inhibitory activity released from activated platelets, releasate was cleared of Kunitz domain-containing forms of PAPP by monoclonal affinity chromatography (see Materials and Methods). Greater than 95% of all factor XIa inhibitory activity contained in platelet releasate is removed with the PAPP (data not shown) as is all radiolabeled factor XIa binding on ligand blot (Fig 2) . Furthermore, factor XIa inhibitory activity (data not shown) and factor XIa ligand-binding activity (Fig 2) is recovered in the eluate of the monoclonal column. When an unrelated monoclonal affinity column is used (antifactor X) 90 2 2% of the factor XIa inhibitory activity is recovered in the effluent and 0 2 1% is detected in the elution. No radiolabeled factor XIa binding activity is found on ligand blot of the elution (data not shown).
Further evidence of the significance of the contribution of platelets to the PAPP factor XIa inhibitory activity is suggested by evaluation of PAPP in plasma and serum. Plasma contains less than 5% of the PAPP factor XIa binding activity found in serum, suggesting that coagulation results in the release of significant amounts of Kunitz domain-containing forms of PAPP (Fig 6) . This is probably caused by the release of PAPP from platelets, because circulating mononuclear cells and polymorphonuclear cells do not contain significant amounts of Kunitz-containing forms of PAPP as dctcrmined by factor Xla ligand blot (Fig  6) .
DISCUSSION
Previous studies have demonstrated that a factor Xla inhibitory activity is present in platelet releasate,n'.2' and that a Kunitzdomain-containing form of the PAPP found in platelets is a potcnt inhibitor of factor XIa.'? Other reports have demonstrated sevcral forms of the PAPP in platclcts and platelet relcasatc, leaving the precise identification of the isoforms opcn to speculation.2x-3' The difficulty in idcntifjing which of the various PAPP species is prcscnt in platclcts is compounded by thc prescncc of up to five diffcrcnt PAPP(r) isoforms, four of which can be present in both full-length (transmembrane) and secreted (truncated) forms, any and all of which may be susceptible to variable degrees of degradation. Thc panel of antibodics used in this study clarifics the moieties present in platelct releasate.
The 112-Kd factor XIa binding activity dctccted by ligand blot (Fig 2) comigrates with bands recognized by antipeptide antibodies directed against several rcgions of the PAPP (Fig 4A) . The antibody pattern is consistent with that prcdictcd of carboxy-terminal-truncated forms of the PAPP as the antiserum directcd against the common cytosolic tail fails to recognize this moiety. The presence of signal seen with antisera directed against the amino-terminus and the PAP suggest that the carboxy-terminal truncation in platelet PAPP occurs at or near the previously described processing site for the transmembrane form of the PAPP.IX The staining with antiserum toward the Kunitz inhibitory domain verifies the presence of at least one of the three Kunitz domain-containing forms of the PAPP in this band, whereas the signal seen with the anti-MRC OX-2 antisera confirms the presence of at least one of the two PAPP isoforms that contain this insert. However, this antibody pattern does not allow a clear distinction between the presence of one or more of the possible forms of PAPP as the relatively broad band at 112-Kd could conceivably rcprcsent several forms of the PAPP migrating in close proximity to each other.
To more specifically identify which forms of the PAPP are present in platelet releasate, we took advantage of the observation that the broad band at I12 Kd is reduced to a doublet migrating at 90 to 95 Kd during thrombin activation of platelets. Both proteolytic fragments of the parent species continue to bc recognized by antisera to the amino-terminus, the Kunitz domain, and the region encoded by exon 14; however, the anti-PAP signal has been lost, suggesting further carboy-tcrminal proteolysis. Only the higher molecular weight member of the doublet is recognized by antisera to thc MRC OX-2 region that, combined with thc presencc of thc Kunitz domain signal, identifies this band as a proteolytic fragment of PAPP-770. The lower molecular weight member of the doublet has the samc antisera recognition pattcrn except for the absence of the MRC OX-2 signal, which identifics it as a proteolytic fragmcnt of PAPP-751. The pcrsistencc of a signal detected with the anti-exon 14 antisera excludes the possibility that the doublet represents sequential proteolysis, because the epitope for this antisera lics carboxy-terminal to the MRC OX-2 sequence (Fig 1B) . The presence of detectable quantities of PAPPr is similarly excludcd, because all bands either before or after thrombin-mediated proteolysis are recognized by the antiexon 14 antisera, which is directed against a pcptidc sequence not present in this species. Comigration of PAPPr with one of the detected bands is unlikely, bccausc the 112-Kd band is completely convcrtcd to thc doublet and no band is seen in the 90-to 95-Kd range bcforc thrombin's effect. Because the effect of thrombin is localized to an amino acid sequence not present in PAPPr, no change in apparent molccular weight of this species would bc anticipated.
Non Reports of the presence of full-length (transmembrane) forms of PAPP in platelets have been p~b l i s h e d .~~+~~ In studies purporting to show full-length forms of PAPP, high concentrations of platelets or concentrated platelet membrane fractions were required for their detection. Microvesicle localization of transmembrane forms of PAPP has also been s~g g e s t e d .~~,~~ The present studies suggest that fulllength PAPP represents a small percentage of PAPP in platelet releasate. However, it is not conclusively demonstrated whether truncated forms of the PAPP are stored and released as such by platelets on activation, or whether platelet activation results in the proteolysis of the transmembrane forms and the release of carboxy-terminal-truncated species. Messenger RNA encoding for transmembrane forms of PAPP have been found in platelets,3O and megakaryocytes have been shown to contain abundant PAPP.29 Therefore, it is likely that platelet PAPP is an endogenous platelet product and the coexistence of both full-length and truncated forms is conceivable. However, the identical size of PAPP in SDS-lysed platelets and platelet releasate argues against large-scale proteolytic conversion of fulllength to secreted forms as a consequence of platelet activation. Moreover, sucrose density gradient studiesZ3 and the thrombin dose-response data of this report suggest that the released PAPP are stored in a granules.
Serum contains substantially more PAPP than plasma (Fig 6) . Our data suggest that this increase is a direct result of the release of PAPP from platelets. Circulating WBC do not bind radiolabeled XIa on ligand blot (this report) and do not contain immunologically detectable concentrations of pAPP.32 The high avidity of Kunitz domain-containing forms of PAPP for factor XIaZ2 implies that platelets contribute significantly to the total factor XIa inhibitory activity found in serum.
Our results suggest that PAPPs account for the majority of the factor XIa inhibitory activity released from platelets. Another factor XIa inhibitor, unrelated to PAPP, has recently been identified in platelet r e l e a~a t e .~~ This inhibitor, called PIXI, is of low molecular mass ( -8 Kd), is found in a low molecular weight filtrate (YM 10; Amicon, Danvers, MA) of platelet releasate, and reportedly accounts for 18% to 54% of the total factor XIa inhibitory activity in platelet r e l e a~a t e .~~ Why this moiety escaped detection in this report is presently unclear but may be related to differences in methodology, as our attempts to locate an ultrafilterable factor XIa inhibitory activity have not as yet been successful.
Thrombin cleaves the secreted forms of PAPP in the platelet releasate. This proteolysis is associated with the loss of reactivity to anti-PAP antiserum, whereas that to the region encoded by exon 14 is retained. There is no loss of epitopes amino terminal to the exon 14 region and the 90-to 95-Kd doublet is stable even in the presence of high concentrations of thrombin or prolonged incubation (Fig  3) . Thus, the thrombin-mediated degradation seems to be restricted to a site within 100 amino acids of the aminoterminus of the PAP. Conceivably the same proteolysis occurs in PAPP-751 and PAPP-770, because both isoforms have identical amino acid sequence in this region, including a single potential thrombin cleavage site (X-Pro-Arg) at amino acid 564-566 (PAPP-751). Cleavage at this site would result in loss of 102 amino acids from the carboxy-terminal end of the secreted forms of PAPP-751 and PAPP-770 consistent with the observed reduction in apparent molecular weight. The relatively high concentrations of thrombin used in these experiments may belie the physiologic relevance of this observation, because the local accumulation of thrombin at the site of a thrombus may be much higher than plasma or serum concentrations. Furthermore, the involvement of as yet unidentified cofactors may obviate the need for high thrombin concentrations. The loss of the carboxyterminal fragment does not seem important for factor XIa inhibitory activity or heparin binding, because no difference in either of these functions was detected between rPAPP-751 before or after thrombin-mediated proteolysis. Nevertheless, this observation may be more than trivial, because similar thrombin cleavage of the transmembrane forms of the PAPP would result in a membrane remnant that contains the intact PAP. Further processing of this remnant could yield the intact 42 amino acid P A P , which could then be deposited in tissues as amyloid under the appropriate pathologic conditions. Recent reports describing the presence of prothrombin message34 and thrombin receptor (S. Coughlin, personal communication, December 1991) in the brain suggest the possible interaction of PAPP and thrombin need not be limited to the circulation and coagulation. 
